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Abstract In the present study, we characterize a polymor-
phism in the CD93 molecule, originally identified as the
receptor for the C1q complement component (i.e., C1qRp,
or AA4.1) in non-obese diabetic (NOD) mice. This allele
carries a coding polymorphism in the first epidermal
growth factor-like domain of CD93, which results in an
amino acid substitution from Asn→His at position 264.
This polymorphism does not appear to influence protein
translation or ecto-domain cleavage, as CD93 is detectable
in bone-marrow-derived macrophage and B-cell precursor
lysates and in soluble form in the serum. The NOD CD93
isoform causes a phenotypic aberrancy in the early B-cell
developmental stages (i.e., pro-, pre-, immature, and transi-
tional), likely related to a conformational variation. Inter-
estingly, the NZB/W F1 strain, which serves as a murine
model of Lupus, also expresses an identical CD93 sequence
polymorphism. Cd93 is located within the NOD Idd13
locus and is also tightly linked to the NZB/W F1 Wbw1 and
Nkt2 disease susceptibility loci, which are thought to
regulate natural killer T (NKT) cell homeostasis. Consistent
with this genetic linkage, we found B6 CD93
−/− and B6.
NOD
Idd13 mice to be susceptible to a profound CD4
+ NKT
cell deficient state. These data suggest that Cd93 may be an
autoimmune susceptibility gene residing within the Idd13
locus, which plays a role in regulating absolute numbers of
CD4
+ NKT cells.
Keywords NOD mice.Idd13.NZB/W F1 mice.Nkt2.
CD93.iNKT cells
Abbreviations
BM Bone marrow
TR Transitional
MZ Marginal zone
iNKT cell Invariant natural killer T cell
NOD Non-obese diabetic
DN Double negative
CD4SP CD4 single positive
Idd Insulin-dependent diabetes
alpha-GalCer Alpha-galactosyl ceramide
LLPC Long-lived plasma cell
Introduction
CD93 is expressed by endothelial cells, cells of myeloid
lineage, platelets, and early hematopoietic stem cells and is
an important lineage-specific marker of early B-cell devel-
opmental stages (Cancro 2004; Danet et al. 2002; Fonseca
et al. 2001; Nepomuceno et al. 1997; Nepomuceno and
Tenner 1998; Petrenko et al. 1999). Normally, CD93 is
expressed at high levels on pro-, pre- and immature bone
marrow (BM) B-cell progenitors as well as transitional
(TR) B cells in the periphery (Cancro 2004). The Cd93
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DOI 10.1007/s00251-010-0442-3gene is located at 84 cM on murine chromosome 2 (Kim et
al. 2000) and encodes a type I O-glycosylated trans-
membrane protein whose domain structure includes an
amino-terminal C-type lectin domain, a tandem array of
five epidermal growth factor (EGF)-like repeats, a single
hydrophobic transmembrane region, and a short cytoplas-
mic domain that contains a PDZ binding domain and a
moesin interaction site (Bohlson et al. 2005; Kim et al.
2000; Norsworthy et al. 1999; Petrenko et al. 1999; Zhang
et al. 2005). This domain structure bears a unique resem-
blance to the selectin family of adhesion molecules (Dean
et al. 2001; Kim et al. 2000; Norsworthy et al. 1999;
Petrenko et al. 1999; Rosen 2004). Additionally, CD93 is
subject to metallo-protease-mediated ecto-domain cleavage
or shedding, which is characteristic of several inflammatory
mediators and adhesion molecules including TNF-α,T G F - α,
TGF-β, EGF, CD44, and L-selectin (Bohlson et al. 2005).
Despite its initial identification as a receptor for the C1q
component of complement and demonstration of an in vivo
kinetic defect in the clearance of apoptotic cells in B6
CD93
−/− mice, the exact in vivo function of this molecule is
yet to be elucidated.
Here, we identify a point mutation in the NOD Cd93
gene, which maps to the Idd13 locus, a region encoding a
high degree of penetrance for diabetes susceptibility in non-
obese diabetic (NOD) mice (Kim et al. 2000; Serreze et al.
1998). Interestingly, we also identified this Cd93 polymor-
phism in NZB/W F1 mice, to which the lupus susceptibility
loci, Wbw1 and Nkt2, are tightly linked (Rahman et al.
2002; Esteban et al. 2003). This point mutation is
associated with aberrant expression of CD93 on NOD and
NZB/W F1 B cells in the pro-/pre-, immature, and TR
subsets as compared with non-autoimmune B6 mice. The
Idd13 and Wbw1 and Nkt2 loci are known to play a role in
the regulation of the invariant natural killer T (iNKT) cell
compartment (Chen et al. 2007; Esteban et al. 2003; Jordan
et al. 2004, Rahman et al. 2002). Since NOD and NZB/W
F1 mice are known to have deficiencies in their iNKT cell
populations (Baxter et al. 1997; Cain et al. 2006; Chen et
al. 2007; Duarte et al. 2004; Esteban et al. 2003; Jordan et
al. 2004; Matsuki et al. 2003; Poulton et al. 2001; Rahman
et al. 2002; Wagner et al. 2005), we sought to determine
whether our finding of a mutation in the NOD and NZB/W
F1 Cd93 gene is linked to regulation of iNKT cells in these
autoimmune-prone strains. We assessed the iNKT cell
populations in non-autoimmune B6 CD93 knockout (B6
CD93
−/−) mice and found that they exhibit a profound
state of CD4+ iNKT cell deficiency. Moreover, we found
that the congenic B6.NOD
Idd13 mice, which carry the
NOD Cd93 gene, also exhibited this CD4+ iNKT cell
deficiency. These findings suggest that Cd93 may be an
important autoimmune susceptibility gene influencing
iNKT cell homeostasis.
Materials and methods
Mice
C57BL/6J, NOD/ShiLtJ, C3H/HeJ, BALB/cJ, NZBWF
1/J, B6.NOD
Idd13-(D2Mit274-D2Mit343) (Jax#3064), NOD.
B6
Idd13-(D2Mit490-Ada) (Jax#2346), NOD.B6
Idd13-(Zfp106-Il1a)
(Jax#3050), and NOD.B6
Idd13-(Il1a-Pcna) (Jax#3051) mice
were obtained from Jackson Laboratories (Bar Harbor,
ME). B6 CD93
−/− mice, constructed from 129-derived ES
cells, were generously donated by Dr. M. Botto and were
backcrossed onto the C57BL/6 background for seven
generations. All animals used in the described experiments
were between 5 and 20 weeks old and were housed in
specific pathogen-free conditions at the University of
Pennsylvania Medical Center. Animal procedures were in
accordance with the Animal Welfare Act.
Abs and flow cytometric analysis
The antibodies used in this study were as follows: PerCP
conjugated anti-CD45R (B220, RA3-6B2), APC conjugat-
ed anti-IgM (II/41), FITC/PE conjugated anti-CD21/35
(7G6), PE conjugated anti-AA4.1, biotinylated 493 mAb
(BD Biosciences, San Diego, CA), mAb1696 (R&D
systems, Minneapolis, MN), and anti-Rat IgG2b (RG7/
11.1) (BD Biosciences). Biotinylated mAb were detected
by streptavidin-allophycocyanin (BD Biosciences). PE
conjugated CD1d tetramer loaded with PBS-57 (Alpha-
galactosyl ceramide (alpha-GalCer) analog) was prepared
by the NIH Tetramer Facility. A total of 1–2×10
6
splenocytes, thymocytes, BM, or peripheral blood lympho-
cytes (PBL) derived cells from age- and sex-matched mice
were surface stained in 96-well microtiter plates with
various combinations of the previously described anti-
bodies. Preparation and staining of livers was done as
previously described (Hammond et al. 2001). Fluorescence-
activated cell sorting (FACS) analysis was performed using
a FACSCalibur (BD Biosciences, San Jose, CA), and the
data were analyzed using FlowJo Software (version 8, Tree
Star, Inc, Ashland, OR).
Bone-marrow-derived macrophages
Bone-marrow-derived macrophages were prepared from
bone marrow progenitors. Briefly, bone marrow was
flushed from femurs of 5- or 10-week-old mice and plated
in cell culture dishes with Dulbecco’s modified Eagle’s
medium (Invitrogen, San Diego, CA) supplemented with
15% L929 cell-conditioned medium (as a source of macro-
phage colony-stimulating factor), 10% heat-inactivated fetal
calf serum, 100 U/ml penicillin/streptomycin (Invitrogen),
and 10 mM HEPES. Additional media was added on day 4,
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until uniform layers of macrophages were established.
sCD93 enzyme-linked immunosorbent assay
Blood was collected by cardiac puncture, placed on ice,
centrifuged for 10 min at 3,200 rpm at 4°C, then serum was
stored at −70°C until use. Mouse serum was assayed for
soluble CD93 using CD93 sandwich enzyme-linked immu-
nosorbent assay (ELISA). Briefly, Immulon 2 HB plates
(Thermo Labsystems, Franklin, MA) were coated overnight
at 4°C with 2 mcg/ml rat monoclonal anti-mouse CD93
(mAB1696, R&D Systems, Minneapolis, MN) in 0.1 M
carbonate buffer, pH 7.4, washed with phosphate buffer
saline containing 0.05% Tween-20 (PBST), and blocked
with PBST containing 3% dried milk (block buffer) for 1 h.
Diluted serum samples were added to wells and incubated
for 1 h. After washing with PBST, 1 mcg/ml sheep anti-
mouse CD93 antibody (AF1696, R&D Systems) was added
to wells for 1 h followed by incubation with anti-sheep horse-
radish peroxidase-conjugated streptavidin (Jackson, Immu-
noresearch, West Grove, PA) diluted 1:2,000 in 1% dried
milk. Sigma fast o-phenylenediamine dihydrochloride perox-
idase substrate (Sigma-Aldrich, St. Louis, MO) was added,
and the change in absorbance at 405 nm was measured.
Western blot
Bone-marrow-derived macrophages or B-cell precursors
(purified with magnetic activated cell separation using B-
cell isolation kit, Miltenyi Biotec, Auburn, CA) were
harvested into lysis buffer (50 mM HEPES, pH 7.0,
150 mM NaCl, 10% glycerol, 1.2% Triton X-100,
1.5 mM MgCl2, 10 mM sodium pyrophosphate, 100 mM
NaF, 1.25 mM sodium orthovanadate, and 1 mM phenyl-
methylsulfonyl fluoride plus 0.15 U/ml aprotinin, 10 mcg/ml
leupeptin, 10 mcg/ml pepstatin A) and incubated on ice for
30 min. After incubation, lysates were centrifuged at
14,000×g for 10 min. The supernatants were collected, and
protein concentrations were determined using the BCA kit
(Pierce Biotechnology, Rockford, IL). Soluble cell extracts
were then separated by 8% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and then trans-
ferred to polyvinylidene difluoride (PVDF). The membrane
was blocked overnight with 5% dry milk in TBST (0.05%
Tween-20 in 20 mM Tris, pH 7.4, 150 mM NaCl). Lysates
from bone-marrow-derived macrophages were probed for
2 h at room temperature with polyclonal anti-CD93
cytoplasmic tail Ab 1150 generated against C-terminal 11
aa of CD93 as previously described (Webster et al. 2000)
and were washed and probed with secondary horseradish
peroxidase conjugate for 1 h at room temperature and
developed using ECL (Amersham Biosciences). Lysates
from bone-marrow-derived B-cell precursors were incubated
overnight with a polyclonal anti-CD93 (Anti-mouse C1qR1,
R&D Systems) and probed with secondary anti-sheep
antibody.
Polymerase chain reaction amplification
and genomic sequencing
Genomic DNA was isolated from tail snip samples ac-
cording to standard protocols. The CD93 gene was poly-
merase chain reaction (PCR) amplified from genomic DNA
using primers designed from the published cDNA sequence
(NCBI accession number NM_010740.3). The forward
oligonucleotide used was 5′-ATGGCCATCTCAACTGG
TTT-3′, and the reverse oligonucleotide used was 5′-
TCAGCAGTCTGTCCCTGGTG-3′. The PCR product of
1,835 bp, covering the first EGF-like domain of CD93, was
isolated on an agarose gel. The bands were cut, and purified
DNA was extracted using the QIAGEN QIAquick Gel
Extraction kit. Samples were sent for sequencing at the
University of Pennsylvania School of Medicine DNA
Sequencing Facility.
Statistical analysis
Statistical analysis was performed using the Mann–Whitney
test, with differences considered significant at p<0.05.
Results
The NOD and NZB/W F1 Cd93 alleles carry
an Asn→His polymorphism at amino acid 264 in its first
EGF-like domain
Genomic Cd93 DNA from B6, BALB/c, NOD, and NZB/W
F1 mice was PCR amplified and sequenced using various
primers to walk along the amplified DNA. A hitherto
unidentified coding polymorphism at cDNA nucleotide
position 790, which converts AAC→CAC, was discovered
in NOD and NZB/W F1 mice (Fig. 1a). This mutation
causes an amino acid substitution from Asn→His at position
264 in the first EGF-like domain of Cd93 (Fig. 1a).
CD93 protein is expressed in cell lysates and serum
of NOD and NZB/W F1 mice
We next sought to determine whether CD93 protein is
expressed in NOD and NZB/W F1 mice. Lysates from in
vitro-differentiated, BM-derived macrophages were pre-
pared and used in Western blot. CD93 protein was detected
in both NOD and NZB/W F1 lysates as assessed using
polyclonal anti-CD93 cytoplasmic tail Ab 1150 (Webster et
Immunogenetics (2010) 62:397–407 399al. 2000). CD93 bands were seen with NOD and NZB/W F1
mice comparable to the B6 and NOR control strains (Fig. 1b).
Lysates of BM-derived macrophages from the B6 CD93
−/−
strain (Norsworthy et al. 2004) were used for a negative
control. We performed a Western blot on purified BM-
derived B-cell precursors to determine whether CD93
protein is detectable on B-cell precursors using a polyclonal
anti-CD93 Ab. B-cell lysates from NOD and B6.NOD
Idd13
mice exhibited a CD93 band similar to B6 counterparts
(Fig. 1b).
CD93 is subject to ecto-domain cleavage by metal-
loproteinase and, as such, exists in soluble form in vivo
(Bohlson et al. 2005). Therefore, as another measure of
protein expression, we assessed serum from NOD and
NZB/W F1 mice for the presence of sCD93 in an ELISA
assay. NOD and NZB/W F1 sera contained measurable
levels of sCD93 at a slightly lower concentration compared
to B6 sera (Fig. 1c). sCD93 levels did not change
significantly with age. Additionally, the concentration of
sCD93 in NOD and NZB/W F1 mice remained constant for
a 738 790 a
C57BL/6 (B6):TGGGGCAGCTCAGGCCCACTCTGTGTCAGCCCCAAGTTTGGTTGCAGTTTCAACAACGGGGGCTGCCAGCAGGATTGCTTCGAAGGTGGC
738 790
BALB/c: TGGGGCAGCTCAGGCCCACTCTGTGTCAGCCCCAAGTTTGGTTGCAGTTTCAACAACGGGGGCTGCCAGCAGGATTGCTTCGAAGGTGGC
TGGGGCAGCTCAGGCCCACTCTGTGTCAGCCCCAAGTTTGGTTGCAGTTTC AACGGGGGCTGCCAGCAGGATTGCTTCGAAGGTGGC NOD
NZB/W F1
TGGGGCAGCTCAGGCCCACTCTGTGTCAGCCCCAAGTTTGGTTGCAGTTTCCACAACGGGGGCTGCCAGCAGGATTGCTTCGAAGGTGGC
TGGGGCAGCTCAGGCCCACTCTGTGTCAGCCCCAAGTTTGGTTGCAGTTTCCACAACGGGGGCTGCCAGCAGGATTGCTTCGAAGGTGGC
5’ TGC AGT TTC AAC AAC GGG GGC TGC 5’- -3’
C
CSFNNGGCQQDCFEGGDGSFRCGCRPGFRLLDDLVTC 261- -297 QQ
H H
CRD N C 2 345 1
SP TM EGF cbEGF TM
b b
c
BM-derived macrophages BM-derived B cell precursors  c
0.7 5 weeks
10 weeks
0.6
250 kD CD93
CD93
0.5
150 kD
0.4 100 kD
β-tubulin
O
D
 
4
0
5
m
m
75 kD 
0.3
0.2
0.1
50 kD
37 kD
0
B6 B6 NOD NOR NZB/W F1
CD93-/-
β-actin
B6
B6
B6.NOD
ldd13
NOD
NOD
NOR
B6
CD93-/-
B6
CD93-/-
NZB/W
F1
Fig. 1 Identification of a coding polymorphism in the first EGF-like
domain of Cd93 in NOD and NZB/W F1 mice. a The Cd93 gene was
PCR amplified from genomic DNA. Sequencing revealed a point
mutation at cDNA nucleotide position 790. The AAC→CAC codon
change in NOD and NZB/W F1 mice led to an amino acid substitution
in the first EGF-like domain of Cd93 at position 264. The first EGF-
like domain in which the defined polymorphism resides is stippled. b
Bone marrow macrophage lysates (left) were separated on an 8%
SDS-PAGE under reducing conditions, transferred to PVDF, and
probed with 5 μg/ml polyclonal anti-CD93 cytoplasmic tail Ab 1150
(black arrow). Isolated bone marrow B-cell lysate immunoblots (right)
were probed with 0.1 μg/ml polyclonal anti-CD93 (anti-C1qR1). The
blots were stripped and re-probed for β-actin or β-tubulin to control
for similar protein loading. The blots are from one experiment,
representative of two, using different animals as a source of bone-
marrow-derived macrophages or B cells. c sCD93 is detected in sera
from NOD and NZB/W F1 mice. Sera were diluted (1:50) and tested
for the presence of sCD93 by sandwich ELISA. Shown is the average
of triplicate wells (± SD) from one experiment, representative of two,
using different animals as a source of sera
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between males and females (data not shown).
Surface CD93 expression by pro-/pre-, immature,
and transitional B cells is deficient in NOD
and NZB/W F1 mice
The expression of CD93 on the various B-cell develop-
mental subsets was characterized using a previously
described flow cytometric gating scheme (Cancro 2004;
Quinn et al. 2006). In the BM, we resolved the pro-/pre-,
immature, and mature recirculating B-cell subsets based on
their expression of IgM and B220 (Fig. 2a). The B220
lo/
IgM− gate contains pro- and pre-B cells, the B220
lo/IgM+
gate contains immature B cells, and the B220
hi/IgM+ gate
contains mature/recirculating B cells. In the peripheral
blood and spleen, we resolved the transitional B-cell
compartment using a B220+/IgM+/CD21/35
lo gate and
the mature/follicular subset using a B220+/IgM+/CD21/
35
int gate (Fig. 2a). CD93 is routinely used as an early B-
cell developmental marker in non-autoimmune strains of
mice (Cancro 2004). In B6 mice, CD93 is expressed at high
levels on pro-/pre- and immature B-cell progenitors in the
BM (Fig. 2a). Its expression continues on peripheral blood
and splenic TR B cells; albeit at a lower level than that seen
on B-cell progenitors in the BM (Fig. 2a). However,
characterization of CD93 expression using the various B-
cell developmental subsets in NOD mice revealed a
deficiency in its expression by pro-/pre-, immature, and
TR B cells in the BM, peripheral blood, and splenic
compartments. Overall, cell surface staining of CD93 using
the AA4.1 mAb revealed three- to sevenfold reduced
expression on the surface of early NOD B-cell progenitors,
as compared to their B6 counterparts (Fig. 2a). CD93
expression on early B-cell subsets of NZB/W F1 mice
followed the staining pattern observed in NOD mice (data
not shown). Both the absolute number and proportion of
CD93+ B cells (i.e., AA4.1+) were significantly reduced
in all early B-cell developmental subsets in NOD and
NZB/W F1 mice, compared with B6 mice (Fig. 2b). We
utilized three distinct mAbs to quantify the cell surface
expression of CD93 in NOD and NZB/W F1 versus B6
mice (Fig. 2c). AA4.1, 493 and 1696 are known to bind
CD93 (McKearn et al. 1984; Rolink et al. 1998). AA4.1,
493 and 1696 staining are deficient in B-cell progenitors
of NOD mice as compared to their B6 counterparts
(Fig. 2c). Our inability to detect surface CD93 in NOD and
NZB/W F1 mice using anti-CD93 mAbs, despite the
presence of CD93 protein expression in BM-derived B-
cell precursors and macrophages using polyclonal anti-
CD93 antibodies (Fig. 1b), is likely due to a conformation
polymorphism in Cd93.
The NOD CD93 defect maps to Idd13
The Cd93 gene maps to 84 cM on murine chromosome 2
(Kim et al. 2000) and falls within the NOD Idd13 locus
(Serreze et al. 1998). Idd13 congenic B6 and NOD mice
were obtained from Jackson Laboratories in order to
establish whether these mice carry the B6 or NOD allele.
Figure 3a summarizes the chromosomal regions intro-
gressed from either the B6 or NOD strains onto the NOD
and B6 backgrounds for each Idd13 congenic strain,
respectively. The B6.NOD
Idd13 strain carries the NOD
chromosome 2 from 52.5 to 84.2 cM. Early B-cell
progenitors from the B6.NOD
Idd13 strain are deficient in
CD93 expression as compared to B6 wild-type counter-
parts, similarly to NOD wild-type mice (Fig. 3b). Three
NOD.B6
Idd13 subcongenic mouse lineages (JAX# 2346,
3050, and 3051) are currently available from Jackson
Laboratories (Fig. 3a). The NOD.B6
Idd13-(D2Mit490-Ada)
strain harbors B6 chromosome 2 in the range of 64.5–
94 cM and, as such, carries the B6 Cd93 allele (Serreze et
al. 1998). Early B-cell progenitors in this strain express
CD93 similarly to B6 wild-type counterparts (Fig. 3b). The
NOD.B6
Idd13-(Zfp106-Il1a) and NOD.B6
Idd13-(Il1a-Pcna) strains
harbor B6 chromosome 2 in the range of 67.2–73 and 73–
75 cM, respectively (Serreze et al. 1998). Early B-cell pro-
genitors from these Idd13 subcongenic strains are deficient
in CD93 expression as compared to B6 wild-type counter-
parts, similarly to NOD wild-type mice (Fig. 3b).
B6 CD93
−/− mice and B6.NOD
Idd13 mice exhibit
a profound state of CD4+ iNKT cell deficiency
The Cd93 locus maps to a region of chromosome 2, which
regulates iNKT cell number and/or function (Chen et al.
2007; Esteban et al. 2003). Therefore, we undertook an
analysis of the iNKT cell compartments of B6 CD93
−/−
(Norsworthy et al. 2004), B6.NOD
Idd13, and NOD mice.
iNKT cells were analyzed in the liver, thymus and spleen
using an alpha-GalCer analog, PBS57-loaded CD1d tetra-
mer. iNKTcells were further resolved into CD4+ and CD4−
subsets in the spleen and liver and CD4 single positive
(CD4SP) and double-negative (DN) subsets in the thymus.
Flow cytometric analysis of lymphoid cells in the liver of
non-autoimmune B6 mice revealed 15.9±5.79% of the
population staining for iNKT cells (Fig. 4a). In contrast,
there was a global deficiency of iNKT cells in lymphoid
populations in the livers of B6 CD93
−/−, B6.NOD
Idd13, and
NOD mice (9.7±4.20%, 7.71±4.29%, and 8.15±3.11%,
respectively, p<0.05 compared with B6 mice, Fig. 4a). We
further resolved the population of iNKTcells into the CD4+
iNKT and CD4− iNKT cell subsets (Fig. 4a, right column),
which allowed us to determine the frequencies of CD4+
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twofold reduction in the frequency of CD4+ hepatic iNKT
cells in B6 CD93
−/−, B6.NOD
Idd13, and NOD, compared
with B6 mice (p<0.05, Fig. 4b). Conversely, the frequency
of CD4− iNKTcells in the liver is similar across each of the
tested strains of mice (p>0.05). Figure 4c shows that the
total number of thymic DN and CD4SP iNKT cells is up to
twofold less in B6 CD93
−/−, B6.NOD
Idd13, and NOD mice,
compared with B6 (p<0.05). Similarly, there is a two- to
threefold reduction of total splenic CD4+ iNKT cells in B6
CD93
−/−, B6.NOD
Idd13, and NOD compared with B6 mice
(p<0.05), while the CD4− iNKT cell numbers is compara-
ble in all strains of mice tested (p>0.05, Fig. 4d). To
exclude the possibility that the reduction of CD4+ iNKT
cells was due to an overall lymphopenia, we analyzed the
total numbers of thymic and splenic lymphocytes and found
that the total number of lymphoid cells in B6, B6 CD93
−/−,
B6.NOD
Idd13, and NOD mice was comparable (p>0.05,
data not shown). Our studies thus confirm that NOD mice
possess a CD4+ iNKT cell deficiency (Baxter et al. 1997;
Godfrey et al. 1997; Hammond et al. 2001) and show that
B6 CD93
−/− and B6.NOD
Idd13 mice exhibit a CD4+ iNKT
cell deficiency similar to NOD mice.
Discussion
In the present study, we identify a hitherto unknown Cd93
polymorphism in NOD mice. The Cd93 locus is tightly
linked to the diabetes susceptibility gene, Idd13, and the
Lupus susceptibility loci, Wbw1 and Nkt2, in the region of
82–84 cM on mouse chromosome 2 (Esteban et al. 2003;
Jordan et al. 2004; Rahman et al. 2002). Both Idd13 and
Nkt2 loci have been implicated in regulating the differen-
tiation of natural killer T (NKT) cells, whose relative
deficiency in NOD and NZB/W F1 mice is thought to play
an important role in the pathogenesis of islet inflammation
(Cain et al. 2006; Chen et al. 2007; Duarte et al. 2004;
Esteban et al. 2003; Jordan et al. 2004; Matsuki et al. 2003;
Poulton et al. 2001; Rahman et al. 2002; Wagner et al.
2005). A subcongenic analysis by Chen et al. revealed that
there are at least two genes within Idd13 that regulate iNKT
cell numbers and that NOD mice congenic for the B6 Idd13
locus were found to be protected from autoimmune diabetes
progression associated with normalization of the NOD
iNKT cell deficient phenotype (Chen et al. 2007). Our data
show that B6.NOD
Idd13 congenic mice, which carry the
NOD Cd93 allele, are characterized by a deficit in the CD4
+ iNKTcell compartment. However, given the large span of
chromosomal DNA introgressed into these congenic mice,
Cd93 is only one among many potential candidate genes
driving the iNKT cell phenotype. Fletcher et al. have
proposed a list of 19 candidate genes, including Cd93,
within the Idd13 region, which may be responsible for
correcting the NOD NKT cell deficiency. Through con-
struction of NOD mice with a congenic insertion of
12.6 Mb of B6-derived sequence within Idd13, the authors
show partial correction of the type 1 NKT cell defect in
NOD mice (Fletcher et al. 2008). Notably, Fletcher et al.
also confirm the genetic location of the Nkt2 NKT cell
control gene to chromosome 2 and provide evidence of the
involvement of more than one locus in this region. Given
the presence of an NOD and NZB/W F1 specific
polymorphism in Cd93, we questioned whether this gene
might be involved in the regulation of iNKT cell homeo-
stasis. We therefore obtained B6 CD93
−/− mice and
analyzed their iNKT cell compartments. These analyses
revealed a profound deficiency in the CD4+ subset of iNKT
cells in CD93
−/− mice. It should be noted that the B6
CD93
−/− mice were constructed using 129 ES cells. Thus, it
remains a possibility that 129 derived alleles within the
Fig. 2 CD93 expression and absolute numbers on the various B-cell
developmental subsets in BM and peripheral lymphoid organs. a The
first column divides lymphoid-gated B cells in the bone marrow into
mature recirculating (B220
hi/IgM+), immature (B220
lo/IgM+), and
pro-/pre-B cells (B220
lo/IgM−). The histograms resolve CD93
expression by AA4.1 antibody on pro-/pre- and immature B cells
(black line) in contrast with mature recirculating B cells (dashed line).
The ratio of the mean fluorescence indices (MFIs) of AA4.1
expression by pro-/pre- and immature B cells to the AA4.1 expression
by mature recirculating B cells is shown as MFI fold Δ on the
histograms. Splenic B-cell developmental subsets are divided into the
marginal zone (MZ) pool (B220+ gated, IgM
hi/CD21/35
hi), FO pool
(B220+ gated, IgM
int/CD21/35
int), and TR pool (B220+ gated, IgM+/
CD21/35
lo). The histograms display AA4.1 expression by the TR pool
(black line) in comparison with the FO pool (dashed line). The ratio of
MFIs of AA4.1 expression by TR B cells and FO B cells is shown as
MFI fold Δ. B cells in the peripheral blood are divided into the mature
recirculating (B220+ gated, IgM+/CD21/35
int) and the TR pool (B220+
gated, IgM+/CD21/35
lo). The histograms display AA4.1 expression by
the TR pool (black line) in comparison with the mature recirculating
pool (dashed line). The MFI fold Δ is an average of at least n=5 mice
per strain shown, and *p<0.05 compared with B6 mice. b The left
panel shows the total numbers of AA4.1+ pro-/pre- and immature B
cells in the BM of B6 (n=12; black bar) and NOD (n=10; white bar)
and NZB/W F1 (n=5,gray bar) mice. The middle panel shows the total
number AA4.1+ TR B cells in the spleen of B6 (n=9;black bar), NOD
(n=9; white bar), and NZB/W F1 (n=5; gray bar) mice. The right
panel shows the percent AA4.1+ cells in the pro-/pre- and immature B
cells in the BM and the TR B-cell compartments in the PBL and spleen
of B6 (n=12 for BM compartments, n=9 for spleen, n=5 for PBL),
NOD (n=10 for BM compartments, n=9 for spleen, n=5 for PBL), and
NZB/W F1 (n=5 for all compartments) mice. Error bars indicate ± SD,
**p<0.01 compared with B6 mice. c The column on the left shows
characteristic AA4.1 expression of B220 cells in the BM of a B6, NOD,
and NZB/W F1 mouse. On the right, AA4.1 and 493 Abs are used in
conjunction on B220+ gated lymphocytes in the BM. The histograms
show expression of mAb1696 by pro-/pre- and immature (black line)i n
contrast with mature recirculating (dashed line) B cells in the BM of
B6, NOD, and NZB/W F1 mice. Staining is representative of at least
n=5 per mouse strain
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Immunogenetics (2010) 62:397–407 403Idd13 locus, other than Cd93, are identical to their NOD
counterparts and cause the observed reduction in CD4+
iNKT cells. In the vicinity of Cd93 (1 Mb upstream and
downstream), 43% of single-nucleotide polymorphisms
(SNPs) in NOD and 129 mice are homologous. However,
among the homologous SNPs, 84% are also homologous
with B6 alleles and can thus be assumed to not contribute to
iNKT cell defects (SNP analysis performed via Mouse
Genome Informatics; http://www.informatics.jax.org). Fur-
thermore, at backcross 7, our CD93
−/− mice are 99.22%
genetically identical with B6 mice. While we believe it
unlikely that there are a significant proportion of remaining
129 derived loci contributing to the observed CD4+ iNKT
cell deficit in CD93
−/− mice, we acknowledge it as an
important caveat.
Several previous reports had noted an overall deficiency
in AA4.1 (i.e., CD93) expression in the bone marrow of
NOD mice (Langmuir et al. 1993; Quinn et al. 2006;
Silveira and Grey 2006). However, these studies did not
further elucidate the specific cell populations with the
deficit or its basis and functional significance. Here, using
three distinct mAbs specific for mouse CD93, we demon-
strated a marked defect in the staining pattern of CD93,
most prominently visible on early B-cell developmental
subsets in the bone marrow. Furthermore, we demonstrated
that NZB/W F1 mice exhibited a similar defect in CD93
expression on early B-cell subsets. Despite this aberrant
staining pattern observed via flow cytometry, we detected
CD93 protein expression using polyclonal antibodies in
Western blot assays of BM-derived macrophages or
b
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Fig. 3 The NOD CD93 defect maps to Idd13. a Chromosomal map
showing regions of either NOD chromosome 2 (white bar)o rB 6
chromosome 2 (black bar) introgressed onto the B6 or NOD
background for each congenic strain obtained from Jackson Labora-
tories. b The left column shows AA4.1 staining on B-cell progenitors
(B220
lo) in the BM for each congenic strain. The middle column
divides B cells in the bone marrow into mature recirculating ( B220
hi/
IgM+), immature (B220
lo/IgM+), and pro-/pre-B cells (B220
lo/IgM−)
for each of the congenic strains. The histograms resolve AA4.1
expression by pro-/pre- and immature B cells (black line) in contrast
with mature recirculating B cells (gray line). The ratio of the mean
fluorescence indices (MFIs) of AA4.1 expression by pro-/pre- and
immature B cells to the AA4.1 expression by mature recirculating B
cells is shown as MFI fold Δ. The MFI fold Δ is an average of at least
n=4 mice per strain shown, and *p<0.05 compared with B6 mice
404 Immunogenetics (2010) 62:397–407purified B-cell precursors in NOD or NZB/W F1 mice.
Moreover, soluble CD93 was detectable in the serum of
NOD and NZB/W F1 mice at a level comparable to that
seen in non-autoimmune mice. Importantly, deficient CD93
staining using three distinct mAbs was associated with an
Asn→His polymorphism at amino acid 264 in NOD and
NZB/W F1 mice. This polymorphism falls within the first
EGF-like domain of Cd93. We believe it likely that this
mutation causes a conformational change that renders NOD
and NZB/W F1 CD93 virtually undetectable by these
monoclonal antibodies.
CD93 was originally isolated and cloned during a search
for myeloid surface molecules involved in the enhancement
of C1q mediated phagocytosis (Nepomuceno et al. 1997).
However, macrophages from CD93-deficient mice are not
deficient in their response to C1q. These mice do, however,
exhibit an impaired uptake of apoptotic cells in vivo
indicating that this receptor contributes to the removal of
dying cells (Rolink et al. 1998). In this context, it has been
suggested that the priming of autoreactive T and B cells in
both autoimmune diabetes and lupus involves an initial
response to apoptotic target cells (Turley et al. 2003). Thus,
Fig. 4 iNKTcell analysis in B6, B6 CD93
−/−, B6.NOD
Idd13 and NOD
mice. a The left panel shows the frequency of iNKT cell staining
(CD3
lo, PBS57-loaded CD1d Tetramer+) in the liver of B6 (n=9,
mean 15.9±5.79%) B6 CD93
−/− (n=7, mean 9.78±4.20%), B6.
NOD
Idd13,( n=5, mean 7.71±4.29%), and NOD (n=5, mean 8.15±
3.11%) mice. The right panel further resolves CD4+ iNKT and CD4−
iNKT cells. b The bar graph indicates the frequency of CD4+ and
CD4− iNKT (CD3
lo, PBS57-loaded CD1d Tetramer+) cells in the
livers of B6 CD93
−/−, B6.NOD
Idd13, and NOD mice. c The bar graph
shows the absolute number of thymic DN and CD4SP iNKT cells
(CD3
lo, PBS57-loaded CD1d Tetramer+) in B6, B6 CD93
−/−, B6.
NOD
Idd13, and NOD mice. d The bar graph indicates the total number
of splenic CD4+ and CD4− iNKT (CD3
lo, PBS57-loaded CD1d
Tetramer+) cells in B6, B6 CD93
−/−, B6.NOD
Idd13, and NOD mice.
Error bars indicate ± SD, *p<0.05 compared with B6 mice
Immunogenetics (2010) 62:397–407 405it may be important to determine whether the Cd93
polymorphism in NOD and NZB/W F1 mice leads to
inefficient clearance of apoptotic bodies, thereby setting the
stage for the initiation of an autoimmune response. In
examining the candidacy of Cd93 as an Idd13 candidate
gene, it will be important to also consider its recognized
role in promoting the uptake of apoptotic cells and immune
complexes by antigen presenting cells.
Our recognition of the NOD Cd93 mutation was a
fortuitous outcome of our phenotypic characterization of
NOD B-cell development (Quinn et al. 2006). It is well
established that CD93 is a marker for early B-cell
developmental subsets (Cancro 2004). The relationship
between CD93 expression by early B-cell progenitors and
iNKT cell homeostasis remains an active area of investiga-
tion in our laboratory. Nevertheless, it is possible that
expression of this protein on developing B cells plays an
independent role in the regulation of B-cell compartment
homeostasis. Indeed, it has been shown that mutations
within the EGF-like domains of the selectin family
members, to which CD93 bears a unique resemblance,
inhibit their activity as adhesion molecules (Kansas 1996;
Rosen 2004). It will therefore be important to determine
whether the NOD polymorphism imparts a defect in
immature/TR B-cell migration dynamics as we previously
demonstrated (Quinn et al. 2006).
Recently, CD93 expression was shown to be re-induced
during plasma cell differentiation from primary B cells
(Chevrier et al. 2009). Furthermore, Chevrier et al. suggest
that while CD93-deficient mice make normal humoral
responses following immunization, they are unable to
maintain long-lived plasma cells (LLPC) within the bone-
marrow niche (Chevrier et al. 2009). Whether this pheno-
type is related to the iNKT cell deficiency seen in these
mice remains to be determined. Nonetheless, it has been
shown that mice lacking iNKTcells cannot sustain antibody
responses and LLPC populations (Galli et al. 2007).
Therefore, it will be important to determine whether the
reliance of LLPC on CD93 is related to their iNKT cell
deficient phenotype. Additionally, the CD1 restricted NKT
cell specific mitogen alpha-GalCer can induce antibody
responses as well as B-cell memory (Galli et al. 2007).
iNKT help to B cells can occur without cognate interaction,
provided that B cells express the costimulatory molecule,
CD40 (Tonti et al. 2009). We are currently investigating the
interplay between CD93, iNKT cells, and B cells in both
early development and later as they differentiate into LLPCs.
In summary, we describe a coding polymorphism in the
first EGF-like domain of Cd93. This gene maps to a
diabetes susceptibility locus on chromosome 2 and is also
tightly linked to the NZB/W F1 Wbw1 and Nkt2 disease
susceptibility loci, which are thought to regulate NKT cells.
Indeed, CD93 deficiency was found to promote a profound
state of CD4+ iNKT cell lymphopenia. These data suggest
that Cd93 may be an autoimmune susceptibility gene and
may play an important role in regulating the CD4+ iNKT
cell compartment. These findings will direct future studies
to determine whether Cd93 is a disease susceptibility gene
in NOD and NZB/W F1 mice and whether similar
polymorphisms exist in type 1 diabetes or lupus patients.
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